Status:
TERMINATED
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This single arm study will assess the efficacy and safety of Tarceva + gemcitabine in patients with locally advanced, unresectable or metastatic pancreatic cancer. Patients will receive Tarceva 100mg ...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- pancreatic cancer, surgically unresectable or with metastases;
- no previous chemotherapy (except concomitant with radiotherapy);
- ECOG 0-2.
Exclusion
- pancreatic cancer without histologic or cytologic confirmation;
- surgical resection possible;
- previous chemotherapy not concomitant with radiotherapy;
- ECOG 3-4.
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00642733
Start Date
August 1 2007
End Date
April 1 2009
Last Update
August 24 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Morelia, Mexico, 58070
2
Tijuana, Mexico, 22320